At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 93 enrolled
Drug / intervention
Sotrovimabdrug
Likely dose
Sotrovimab 500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 Infection in Immunocompromised Individuals With Impaired SARS-CoV-2 Humoral Immunity
In Brief
A Phase 2 clinical trial evaluating Sotrovimab for SARS CoV 2 Infection. Completed, enrolled 93 participants across 3 sites.
Detailed Summary
This is an open-label study examining the safety and tolerability of sotrovimab, administered in two sequential doses as prophylaxis in immunocompromised patients with impaired humoral immunity against SARS-CoV-2.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS CoV 2 Infection
CountriesUnited States
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedJan 2022
Enrollment StartFeb 2022
Primary CompletionFeb 2023
TodayJul 2026
First PostedJan 27, 2022
Enrollment StartFeb 7, 2022
Primary CompletionFeb 28, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 4.4 years ago
Interventions
Sotrovimabdrug
Two intravenous (IV) doses of sotrovimab were administered over the study period, the first 500mg, and the second 2000mg, in light of the reduced antiviral neutralization of sotrovimab against the BA.2 subvariant.